```markdown
---
title: Complete Response Letters – NDA 214835 (Risperidone ISM Injectable Suspension)
applicant: Laboratorios Farmacéuticos ROVI, S.A.
contact_address: c/o PharmaLex, 1700 District Avenue, Suite 100, Burlington, MA 01803
product: Risvan (risperidone ISM) intramuscular injectable suspension
application_number: NDA 214835
letters:
  - date: 2023-07-27
    reference_id: 5216371
    addressee: Anna Perelka
    submission_date: 2020-11-24
    complete_response_submitted: 2023-01-27
    signed_by: Bernard Fischer, MD
  - date: 2022-07-15
    reference_id: 5014501
    addressee: Nick Palmer
    submission_date: 2020-11-24
    complete_response_submitted: 2022-01-18
    signed_by: Tiffany R. Farchione, MD
  - date: 2021-09-24
    reference_id: 4861793
    addressee: Nick Palmer
    submission_date: 2021-01-08
    amendments: [2021-09-10, 2021-09-23]
    signed_by: Tiffany R. Farchione, MD
---

## Critical Data

| Field                        | Value                                                                 |
|-----------------------------|-----------------------------------------------------------------------|
| NDA Number                  | 214835                                                                |
| Product Name                | Risvan (risperidone ISM)                                              |
| Product Formulation         | Intramuscular injectable suspension                                   |
| Applicant                   | Laboratorios Farmacéuticos ROVI, S.A.                                 |
| Submission Address          | c/o PharmaLex, 1700 District Avenue, Suite 100, Burlington, MA 01803  |
| Key Facility (FEI)          | Laboratorios Farmacéuticos ROVI, S.A. – FEI: 3010705046               |
| Pending Sites (2021 Letter) | Rovi Pharma Industrial Services SA (FEI: 3002989591, 3007512884)     |
| CRL Dates                   | July 27, 2023; July 15, 2022; September 24, 2021                      |
| Regulatory Contacts         | Simran Parihar, Eugene Lee, Latrice Wilson                            |
| Common Deficiencies         | DMF inadequacies, facility inspection, labeling, human factors        |
| Required Safety Updates     | Specified in detail; consistent across all letters                    |
| Resubmission Instructions   | Respond within 1 year; label "RESUBMISSION"; clarify CR intent        |

---

# Complete Response Letters  
## NDA 214835 – Risperidone ISM Injectable Suspension  
### Laboratorios Farmacéuticos ROVI, S.A.  
c/o PharmaLex  
1700 District Avenue, Suite 100  
Burlington, MA 01803  

---

## Letter Dated July 27, 2023

### Addressee  
Anna Perelka  
Associate Director, Regulatory Affairs  

### Application Details  
- NDA Submission Date: November 24, 2020  
- Complete Response Submitted: January 27, 2023  
- Product: Risvan (risperidone ISM) intramuscular injectable suspension  
- Reference ID: 5216371  

### Decision  
The application cannot be approved in its present form.

### Facility Inspections  
Deficiencies identified during pre-approval inspection of:  
- Laboratorios Farmacéuticos ROVI, S.A. (FEI: 3010705046)  
Satisfactory resolution is required.

### Prescribing Information  
FDA reserves comment until application is otherwise adequate.  
Refer to:  
- [Prescription Drug Labeling Resources](https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources)  
- Pregnancy and Lactation Labeling Final

### Safety Update Requirements  
Provide updates as follows:

1. Describe any significant changes or findings in the safety profile.
2. For sections on adverse events:
   - Present new safety data from studies/clinical trials using original format.
   - Provide tabulations of new data combined with original data.
   - Include comparison tables of adverse event frequencies.
   - For other indications, provide separate tables.
3. Retabulate reasons for premature trial discontinuation.
4. Provide case report forms and narrative summaries for:
   - Subjects who died
   - Subjects who dropped out due to adverse events
   - Serious adverse events
5. Describe changes in incidence of common, less serious adverse events.
6. Provide updated exposure information (number of subjects, person time).
7. Provide safety summary of worldwide experience and usage estimates.
8. Submit English translations of foreign approved labeling not previously submitted.

### Other Instructions  
- **Resubmission Requirement**: Within 1 year under 21 CFR 314.110  
- **Resubmission Labeling**:  
  - Clearly marked "RESUBMISSION" in bold on cover letter  
  - State complete response intent

### Communication  
For questions, contact:  
Simran Parihar, PharmD  
Email: simran.parihar@fda.hhs.gov  

### Signed By  
Bernard Fischer, MD  
Deputy Director, Division of Psychiatry  
Office of Neuroscience  
Center for Drug Evaluation and Research  

---

## Letter Dated July 15, 2022

### Addressee  
Nick Palmer  
Senior Manager, Consulting and Scientific Affairs  

### Application Details  
- NDA Submission Date: November 24, 2020  
- Complete Response Submitted: January 18, 2022  
- Reference ID: 5014501  

### Decision  
The application cannot be approved in its present form.

### Product Quality  
- Application refers to Drug Master File (DMF)  
- DMF referenced found inadequate  
- Deficiencies communicated to DMF holder on July 15, 2022  
- Applicant must include date of DMF amendment in response

### Facility Inspections  
- Deficiencies conveyed during inspections of listed facilities:  
  - Laboratorios Farmacéuticos ROVI, S.A. (FEI: 3010705046)  

### Pages 67-68 Concern  
Study Code: UDMI-PVP-18-018/00  
- Requalification data from 03SEP2019 run incomplete  
- Exposed results post-incubation and positive control information missing

### Human Factors  
- Two participants had difficulty administering full dose due to viscosity  
- IFU lacks explicit instruction to inject slowly and steadily  
- Revise IFU with clear instructions  

### Prescribing Information  
Refer to SRPI checklist and submit updated labeling in SPL format.  
Resources:  
- [Prescription Drug Labeling Resources](https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources)  
- [Pregnancy and Lactation Labeling Final Rule](https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule)  
- [Structured Product Labeling](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

### Safety Update Requirements  
Same as listed in July 27, 2023 letter.

### Other Instructions  
Same resubmission policies as previous letter.

### Communication  
For questions, contact:  
Eugene Lee  
Regulatory Project Manager  
Email: C.Eugene.Lee@fda.hhs.gov  

### Signed By  
Tiffany R. Farchione, MD  
Director, Division of Psychiatry  

---

## Letter Dated September 24, 2021

### Addressee  
Nick Palmer  

### Application Details  
- NDA Submission Date: January 8, 2021  
- Amendments Dated: September 10, 2021, September 23, 2021  
- Reference ID: 4861793  

### Decision  
The application cannot be approved in its present form.

### Ophthalmology  
- August 21, 2021: FDA request for data clarification  
- Applicant committed to resubmission no earlier than October 15, 2021  
- Fully address questions 1, 2, 4, 5, and 6 in resubmission  

### Human Factors  
- HF validation study shows need for UI improvements  
- Issues with full dose injection due to viscosity  

### Product Quality  
- Establish direct PLGA testing per May 21, 2021 response  
- Perform thermal cycling study of powder syringe (PLGA + risperidone)

### Biopharmaceutics  

#### In Vitro Drug Release Testing (IVRT)

1. High inter/intra-batch variabilities observed  
   - Source: Drug quality, dissolution, analytical method  
   - Action: Investigate and provide confirmation data  

2. Proposed dissolution acceptance criteria too permissive  
   - Acceptable only if supported by “safe space” models (e.g., IVIVC)

### Microbiology  
- Referenced DMF found inadequate  
- Deficiencies sent to holder May 11, 2021  
- Include amended date in response  

### Closure Integrity  
- Provided validation reports (UDMI-IVP-21-013/00 and UDMI-IVP-21-014/00) use vacuum only  
- FDA recommends both vacuum and pressure conditions  
- Commit to performing additional testing  

### Facility Inspections  
- Pending inspections:  
  - Rovi Pharma Industrial Services SA (FEI: 3007512884; Spain)  
  - Rovi Pharma Industrial Services SA (FEI: 3002989591; Spain)  
- Delayed due to COVID-19 travel restrictions  
- Application requires inspection before approval  
- Reference: [2020 Guidance on Facility Assessments During COVID-19](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-otherstakeholders)

### Prescribing Information  
Same instructions as previous letters.

### Carton and Container Labeling  
Submit revised draft labels based on FDA’s September 17, 2021 proposal

### Proprietary Name  
- Risvan: Acceptable pending approval  
- Resubmit name in response

### Safety Update Requirements  
Same as in other letters.

### Other Instructions  
Same resubmission and labeling instructions as previous letters.

### Communication  
For questions, contact:  
Latrice Wilson  
Senior Regulatory Project Manager  
Phone: (240) 402-5317  

### Signed By  
Tiffany R. Farchione, MD  
Director, Division of Psychiatry  
```